Skip to content
Triangle logo TriangleGet started
← Study library

NCT03930771 · REGISTRY CONDITION SEARCH

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2022-08-09

This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities. Enrolled patients will receive treatment in 28-day cycles: capecitabine 1500mg/m2 per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14 and oral temozolomide 150 to 200 mg/m2 on days 10 through 14. This will be followed by 14 days off treatment. MRI imaging will be completed after every two cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Subjects With Radiographic Response, as Defined by the RECIST Criteria.

→

outcome · POSTED

Effect of the CAP and TMZ Combination on Pituitary Function, Measured by Changes in Pituitary Hormone Secretion in Patients

→

outcome · POSTED

Safety, as Measured by the Number of Subjects With at Least One AE

→

outcome · POSTED

Tolerability of the TMZ and Capecitabine Combination, as Measured by Number of Participants With a Dose-limiting Toxicity

→

outcome · POSTED

Tumor Invasiveness and Aggressiveness, Determined by Assessing the Relationship Between Select Indicators With Response to Chemotherapy, Time to Progression, and Tumor Invasiveness.

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria:: * Male or female ≥ 18 years of age. * Patients with nonfunctioning tumors must have histologically confirmed pituitary adenoma. Patients with functioning tumors do not require surgery if there is clear diagnosis of functioning pituitary adenomas established based on endocrine evaluation. * Karnofsky performance status ≥ 70%. * Life expectancy of greater than six months. * Residual or recurrent pituitary adenoma ≥1cm in maximal diameter on MRI Brain; patient must have received at least one prior therapy, such as surgery, radiation and/or medical therapy. * Patients must have normal organ and marrow function as defined below. NOTE: Laboratory values must be taken within 7 days prior to chemotherapy administration. Transfusions and/or growth factor support may not be used to meet this criteria): * Platelet count ≥ 100 × 109/L. * Hemoglobin ≥ 9 g/dL. * WBC ≥ 3 × 109/L * Absolute neutrophil count (ANC) ≥ 1.5 × 109/L. * Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 x ULN if Gilbert's disease is documented. * Aspartate transaminase (AST) ≤ 2.5 ULN. * Alanine transaminase (ALT) ≤ 2.5 ULN. * Serum creatinine ≤ 1.5 × ULN OR creatinine clearance≥60mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Patients must be able to undergo a MRI Brain/Pituitary * For women of child-bearing potential and for men with partners of child-bearing potential, subject must agree to take contraceptive measures for duration of treatment and at least 6 months after the last dose of chemotherapy. * Patients must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior temozolomide and/or capecitabine therapy for treatment of the pituitary tumor. * Other active malignancy outside of nonmelanoma skin cancer (patients in remission and with prior treatment more than two years ago will be accepted into trial). * Clinically significant renal, hematologic or hepatic abnormalities. * Use of Vitamin K antagonists such as warfarin (concentrations may be altered by concomitant use of capecitabine) * Uncontrolled concurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance with study requirements * History of deficient dihydropyrimidine dehydrogenase activity. * History of immunodeficiency. * Patients who are taking any other concurrent investigational therapy. * Patients who are pregnant or breastfeeding. * Patients who have had prior radiation treatment in the last six months * Patients who have had prior pituitary surgery within the last two months
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    All subjects will receive: 1. Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14. 2. Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14. After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity).
    intervention Names
    1. Drug: Capecitabine
    2. Drug: Temozolomide
    label
    All Patients
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. All Patients
    description
    1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
    name
    Capecitabine
    type
    DRUG
  2. arm Group Labels
    1. All Patients
    description
    150 to 200 mg/m2 orally on days 10 through 14.
    name
    Temozolomide
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
1
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Evaluation of Target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum onstudy (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
    measure
    Number of Subjects With Radiographic Response, as Defined by the RECIST Criteria.
    time Frame
    6 months
secondary Outcomes
  1. description
    Serum prolactin, IGF-1, ACTH, FSH, LH and TSH levels are used to assess changes in pituitary hormone function. These tests will only be repeated if found to be abnormal at baseline.
    measure
    Effect of the CAP and TMZ Combination on Pituitary Function, Measured by Changes in Pituitary Hormone Secretion in Patients
    time Frame
    At baseline and every 8 weeks, up to 6 months
  2. measure
    Safety, as Measured by the Number of Subjects With at Least One AE
    time Frame
    6 months
  3. measure
    Tolerability of the TMZ and Capecitabine Combination, as Measured by Number of Participants With a Dose-limiting Toxicity
    time Frame
    6 months
  4. description
    Tumor invasiveness and aggressiveness, determined by assessing the relationship between select indicators (including Ki67 nuclear labelling index, p53 expression, MGMT expression/methylation status, and additional tumor genetic profiling) with response to chemotherapy, time to progression, and tumor invasiveness (based on the Knosp criteria).
    measure
    Tumor Invasiveness and Aggressiveness, Determined by Assessing the Relationship Between Select Indicators With Response to Chemotherapy, Time to Progression, and Tumor Invasiveness.
    time Frame
    6 months
Full study description
brief Summary
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities. Enrolled patients will receive treatment in 28-day cycles: capecitabine 1500mg/m2 per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14 and oral temozolomide 150 to 200 mg/m2 on days 10 through 14. This will be followed by 14 days off treatment. MRI imaging will be completed after every two cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-2c879292b98ed6352721
      requested nct id
      NCT03930771
      primary nct id
      NCT03930771
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      3ef78ce4ecba793eb2b9932bd51babe9d6d7cee15aba0d82d9e98002353b720a
      payload sha256
      d3c5bc133e041891aaf2262bf98a57d54f856b9bd855e8c2a801120a488b9f3e
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-2c879292b98ed6352721
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03930771
      occurrences
      1. context exact
        NCT03930771
        end
        11
        exact text
        NCT03930771
        start
        0
      offset unit
      unicode_code_points
      query cond
      Pituitary Tumors
      query disease state id
      ds-pituitary-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-pituitary-tumors-000.json
      source file sha256
      3ef78ce4ecba793eb2b9932bd51babe9d6d7cee15aba0d82d9e98002353b720a
      source json pointer
      /studies/4/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6addafc8aaeb6dbdd733cccc31da4a6fe640b2acae34f5393b499d461a34df08

    Preserved source evidence · Not medical advice